These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 30456574)
1. CCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancer. Pervaiz A; Zepp M; Mahmood S; Ali DM; Berger MR; Adwan H Cell Oncol (Dordr); 2019 Feb; 42(1):93-106. PubMed ID: 30456574 [TBL] [Abstract][Full Text] [Related]
2. Antineoplastic effects of targeting CCR5 and its therapeutic potential for colorectal cancer liver metastasis. Pervaiz A; Zepp M; Georges R; Bergmann F; Mahmood S; Faiza S; Berger MR; Adwan H J Cancer Res Clin Oncol; 2021 Jan; 147(1):73-91. PubMed ID: 32902795 [TBL] [Abstract][Full Text] [Related]
3. The CCR5 antagonist maraviroc causes remission of pancreatic cancer liver metastasis in nude rats based on cell cycle inhibition and apoptosis induction. Huang H; Zepp M; Georges RB; Jarahian M; Kazemi M; Eyol E; Berger MR Cancer Lett; 2020 Apr; 474():82-93. PubMed ID: 31954769 [TBL] [Abstract][Full Text] [Related]
4. CCR5 blockage by maraviroc induces cytotoxic and apoptotic effects in colorectal cancer cells. Pervaiz A; Ansari S; Berger MR; Adwan H Med Oncol; 2015 May; 32(5):158. PubMed ID: 25840792 [TBL] [Abstract][Full Text] [Related]
5. Anti-tumor potential of high salt in breast Cancer cell lines. Sharma M; Dey U; Das AS; Olymon K; Kumar A; Mukhopadhyay R Mol Biol Rep; 2024 Sep; 51(1):1002. PubMed ID: 39305332 [TBL] [Abstract][Full Text] [Related]
6. Asperolide A prevents bone metastatic breast cancer via the PI3K/AKT/mTOR/c-Fos/NFATc1 signaling pathway. Jiang W; Rixiati Y; Huang H; Shi Y; Huang C; Jiao B Cancer Med; 2020 Nov; 9(21):8173-8185. PubMed ID: 32976685 [TBL] [Abstract][Full Text] [Related]
7. CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth. Casagrande N; Borghese C; Visser L; Mongiat M; Colombatti A; Aldinucci D Haematologica; 2019 Mar; 104(3):564-575. PubMed ID: 30309853 [TBL] [Abstract][Full Text] [Related]
8. Essential roles of the interaction between cancer cell-derived chemokine, CCL4, and intra-bone CCR5-expressing fibroblasts in breast cancer bone metastasis. Sasaki S; Baba T; Nishimura T; Hayakawa Y; Hashimoto S; Gotoh N; Mukaida N Cancer Lett; 2016 Aug; 378(1):23-32. PubMed ID: 27177471 [TBL] [Abstract][Full Text] [Related]
9. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis. Jin K; Pandey NB; Popel AS Breast Cancer Res; 2018 Jun; 20(1):54. PubMed ID: 29898755 [TBL] [Abstract][Full Text] [Related]
10. Cellular effect of styrene substituted biscoumarin caused cellular apoptosis and cell cycle arrest in human breast cancer cells. Perumalsamy H; Sankarapandian K; Kandaswamy N; Balusamy SR; Periyathambi D; Raveendiran N Int J Biochem Cell Biol; 2017 Nov; 92():104-114. PubMed ID: 28958615 [TBL] [Abstract][Full Text] [Related]
11. Antitumor Effects of Ruyiping on Cell Growth and Metastasis in Breast Cancer. Li Z; Sun X; Liu X; Sun Z; Li J Cancer Biother Radiopharm; 2019 Jun; 34(5):297-305. PubMed ID: 30901274 [No Abstract] [Full Text] [Related]
12. Chemokine C-C motif receptor 5 and C-C motif ligand 5 promote cancer cell migration under hypoxia. Lin S; Wan S; Sun L; Hu J; Fang D; Zhao R; Yuan S; Zhang L Cancer Sci; 2012 May; 103(5):904-12. PubMed ID: 22380870 [TBL] [Abstract][Full Text] [Related]
13. Naringenin inhibits migration of breast cancer cells via inflammatory and apoptosis cell signaling pathways. Zhao Z; Jin G; Ge Y; Guo Z Inflammopharmacology; 2019 Oct; 27(5):1021-1036. PubMed ID: 30941613 [TBL] [Abstract][Full Text] [Related]
14. An agent-based model of triple-negative breast cancer: the interplay between chemokine receptor CCR5 expression, cancer stem cells, and hypoxia. Norton KA; Wallace T; Pandey NB; Popel AS BMC Syst Biol; 2017 Jul; 11(1):68. PubMed ID: 28693495 [TBL] [Abstract][Full Text] [Related]
15. CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells. Singh SK; Mishra MK; Eltoum IA; Bae S; Lillard JW; Singh R Sci Rep; 2018 Jan; 8(1):1323. PubMed ID: 29358632 [TBL] [Abstract][Full Text] [Related]
16. In vitro effects of the CCR5 inhibitor maraviroc on human T cell function. Arberas H; Guardo AC; Bargalló ME; Maleno MJ; Calvo M; Blanco JL; García F; Gatell JM; Plana M J Antimicrob Chemother; 2013 Mar; 68(3):577-86. PubMed ID: 23152485 [TBL] [Abstract][Full Text] [Related]
17. CCR5 antagonist maraviroc alleviates doxorubicin-induced neuroinflammation and neurobehavioral deficiency by regulating NF-κB/NLRP3 signaling in a breast cancer mouse model. Wu Y; Che J; Dong J; Zhang X; Deng Y; Chen W; Zhang J Neuropharmacology; 2024 Aug; 254():109981. PubMed ID: 38704022 [TBL] [Abstract][Full Text] [Related]
18. Gold clusters prevent breast cancer bone metastasis by suppressing tumor-induced osteoclastogenesis. Zhang Z; Yao Y; Yuan Q; Lu C; Zhang X; Yuan J; Hou K; Zhang C; Du Z; Gao X; Chen X Theranostics; 2020; 10(9):4042-4055. PubMed ID: 32226538 [No Abstract] [Full Text] [Related]
19. Evodiamine induces apoptosis and inhibits metastasis in MDA‑MB-231 human breast cancer cells in vitro and in vivo. Du J; Wang XF; Zhou QM; Zhang TL; Lu YY; Zhang H; Su SB Oncol Rep; 2013 Aug; 30(2):685-94. PubMed ID: 23708383 [TBL] [Abstract][Full Text] [Related]
20. Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis. Cai D; Cao J; Li Z; Zheng X; Yao Y; Li W; Yuan Z BMC Cancer; 2009 Apr; 9():102. PubMed ID: 19338666 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]